- Previous Close
2.7700 - Open
2.7700 - Bid 2.4000 x --
- Ask 2.4100 x --
- Day's Range
2.3300 - 2.7800 - 52 Week Range
2.0200 - 3.0100 - Volume
115,266 - Avg. Volume
20,949 - Market Cap (intraday)
49.012M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.00
Bioretec Oy, a medical device company, develops, manufactures, and markets bioresorbable orthopedic implants for the repair of bone and soft tissue injuries in children and adults worldwide. The company offers Activa IM-Nail, a bioabsorbable option for pediatric forearm intramedullary nailing; ActivaNail, an implant that is be used in upper or lower limbs to ensure successful bone regeneration; ActivaPin, a bioabsorbable implant for upper and lower limb fractures; and ActivaScrew, an absorbable surgical implant that is used in fracture treatment, osteotomy, arthrodesis, and bone graft surgery. It also provides ActivaScrew Cannulated that offers a range of fully threaded and partially threaded cannulated screws for fixation of fractures and osteotomies; ActivaScrew Interference, a tool for multiple uses regarding bone fractures, osteotomies, arthrodesesm, and bone grafts; ActivaScrew Interference TCP, a biocomposite interference screw; and RemeOs Screw, a magnesium screw implants. The company was formerly known as BCI Bioabsorbable Concepts Oy. Bioretec Ltd. was incorporated in 1998 and is headquartered in Tampere, Finland.
bioretec.comRecent News: BRETEC.HE
View MorePerformance Overview: BRETEC.HE
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BRETEC.HE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BRETEC.HE
View MoreValuation Measures
Market Cap
49.01M
Enterprise Value
46.91M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.46
Price/Book (mrq)
7.58
Enterprise Value/Revenue
11.51
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
-0.1700
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Research Analysis: BRETEC.HE
View MoreCompany Insights: BRETEC.HE
BRETEC.HE does not have Company Insights